Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study - sprookjes - yvandenbroek - TriplyDB

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

http://www.wikidata.org/entity/Q28348036

about

KSR1 is a functional protein kinase capable of serine autophosphorylation and direct phosphorylation of MEK1 Predominance of CIN versus MSI in the development of rectal cancer at young age.Molecular Profiling in Resectable Colorectal Liver Metastases: The Role of KRAS Mutation Status in Assessing Prognosis in the Preoperative Setting Molecular profiling in the treatment of colorectal cancer: focus on regorafenib Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?Can K-ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review Colorectal Cancer Biomarkers: Where Are We Now?Treatment of metastatic colorectal cancer: focus on panitumumab Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.Prediagnostic Physical Activity and Colorectal Cancer Survival: Overall and Stratified by Tumor Characteristics.KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803 Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials.RAS and BRAF in metastatic colorectal cancer management Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features Yttrium-90 radioembolization for colorectal cancer liver metastases in KRAS wild-type and mutant patients: Clinical and ccfDNA studies.Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.Differences in survival between colon and rectal cancer from SEER data.Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data.p120RasGAP is a mediator of rho pathway activation and tumorigenicity in the DLD1 colorectal cancer cell line.The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: a pilot study.Molecular detection (k-ras) of exfoliated tumour cells in the pelvis is a prognostic factor after resection of rectal cancer?Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors Fast simultaneous detection of K-RAS mutations in colorectal cancer.Colorectal carcinomas in MUTYH-associated polyposis display histopathological similarities to microsatellite unstable carcinomas Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumor.KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes.KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis.Adjuvant Chemotherapy for Stage II Colon Cancer: The Role of Molecular Markers in Choosing Therapy Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis.Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine.Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status.

P2860

Q24626430-679FB187-57A3-475F-8F26-D8613271B279 Q24793045-E0933F52-A05C-4DD3-964A-AF435F568A3A Q26749002-5A28BF27-0442-47AF-BF49-5A1B3C42EDE2 Q26778296-CEDC594A-4AA0-4297-895B-12F76CEAEB5E Q26795609-B58B7DBB-6431-4C10-8165-D662184DD33D Q26828992-152681B0-7AD6-4BC6-ACB8-71D6CA1350C5 Q26863194-24E2817A-90BA-4D3C-898D-AE97E6FF7B60 Q27003134-D595A74F-4E97-4D47-90E7-1FE13BA815BB Q27022954-4081EF8F-85A9-43F2-AE7B-92538C1899C9 Q27313799-F6725EDC-B7C0-404C-B75A-90C6E30A75AE Q27347219-4513B718-5646-4023-94D3-72796162E952 Q27851532-9BEF051E-1D06-4D04-A288-FDB92FB95E87 Q27851892-6C14A0BE-3621-4937-8170-ACF71F6FE149 Q27852414-66015433-6CA3-4E45-8F2E-7E4429AAC52A Q28074175-E5C4C6DA-F605-4A06-943E-9359D79261AB Q28258483-6FBDE2B9-E47A-4B83-8CDC-0E12FF3A94B8 Q28284149-5F70791B-2536-4F6C-B9EA-CBEF108912FA Q30353464-48A11B99-5C34-448A-A43E-CB22F3381DE3 Q30405398-06E8962F-AA51-40F1-849B-212138576FE5 Q30699655-70B32498-58E1-47EC-92DD-EDB6976D3BE0 Q30884552-C02ABBBC-7AE7-4452-A4FC-7E8A5019910D Q31148783-4FF8F1E9-978F-4A53-8640-5039F2A666AC Q31157634-FAEA9679-E0AB-4672-B42E-59C5DBFF649E Q33355208-015F243F-0E54-4B2F-B712-EAB50E65A421 Q33385005-BCD97414-F75C-41BF-BDF6-53181FF97A2E Q33465331-9A6D7CF3-DD5F-47ED-BFB7-7F68A67E9562 Q33467568-699582C7-CE20-45ED-99FB-6995CB02D60E Q33510817-51AFAEFB-29E4-4605-8F2A-CE40395F6EB8 Q33519564-DC3096B1-DB22-4EE4-8027-9D066AEFF3AB Q33541307-41BC0F40-44D6-4B8C-8908-545DE9715A7A Q33541323-938B3312-751C-4878-AD88-B95575A97AE1 Q33591865-DEBB6913-4510-47A6-BBB1-8E579B0EC13A Q33591943-BAEA4C22-99D7-426E-9C81-2BABB2981A10 Q33599123-388AB2B5-5241-48A1-BCC2-DA1A365DFA09 Q33682949-17F0FEAD-D3DD-4356-BB90-75F47253C5E2 Q33690682-00FCE35F-A021-4964-9F94-26051DA6B22D Q33693309-6428C6BA-BD86-4550-A83A-5C3B3F543727 Q33723645-9CEA1173-54E1-4153-A4A2-D3C512393376 Q33732199-8E9E0D38-8562-47E9-AB56-D6CDFC0BF7FC Q33737099-196DBB79-032E-492D-9717-C5E30A8E83D9

P2860

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

http://www.wikidata.org/entity/Q28348036

description

2001 nî lūn-bûn

@nan

2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

@ast

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

@en

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

@en-gb

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

@nl

type

label

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

@ast

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

@en

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

@en-gb

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

@nl

prefLabel

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

@ast

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

@en

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

@en-gb

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

@nl

P1433

Q28348036-5FBDAEBD-B7D7-40A8-B976-0CD61DDDC95E

P1476

Q28348036-61B04B82-2F4B-4B21-8831-2FCD92FE8516

P2093

Q28348036-02C90F9B-462D-42B3-A605-E485F6F66A19

Q28348036-058F944D-771B-4859-9D32-FC9B123AADE2

Q28348036-0792CA5A-3255-4C2E-8FD6-17870C6BC9BD

Q28348036-09F1B08F-6CD7-430F-B01E-EA4B324472F4

Q28348036-0C1866E9-7ADB-4165-9835-E0B87C7E04DB

Q28348036-10DA6938-FB13-4A65-8923-7713B2A56EC3

Q28348036-1133D8B8-AE9C-4979-9A6C-593DAFB89650

Q28348036-15DDB121-B9A0-4540-9EBA-7A265AC4335D

Q28348036-16FBFE98-7146-4BBF-9E0E-B47A4AA5ADF1

Q28348036-19F830AC-84F9-4911-B059-3C192B334936

P2888

Q28348036-2F72F65E-A2AA-458F-9619-37119FF84DAF

P304

Q28348036-E0A6E478-6036-491F-A3AD-EE01EFC70488

P31

Q28348036-C85D83D7-A62B-4543-ADA8-EB12A09C9756

P3181

Q28348036-84A7B463-A789-4526-A365-368A126940F8

P356

Q28348036-7E1B3B69-CCA4-411C-8B69-53A54E8CFF2C

P407

Q28348036-AE5043F6-6907-42B6-9C5D-159BEDD9258E

P433

Q28348036-0130BE3E-4E5E-45FC-B180-5ABC02691819

P478

Q28348036-0E9B8FFA-1120-42B3-B97B-C020BB9E371E

P50

Q28348036-11C2004E-EA0F-4D44-84EF-E879B73ADA85

Q28348036-258B241E-0AAD-469E-AC3A-214D50BEF74C

Q28348036-264C5804-05D5-46FD-8DE8-53B5FB7B7577

Q28348036-71B388AE-D4F9-4C74-A35B-6C1FA0AC4033

Q28348036-7A3DDD57-403F-4158-B841-D237E76A98D2

Q28348036-8EBF4B5D-B569-43E7-9491-7DF2A8EF2648

Q28348036-ABBBAA2B-3108-4389-80E2-4A521C00F083

Q28348036-C4B5BC47-1743-47DF-A1F2-DE2A347CF2DB

Q28348036-C9AE1331-442B-4A7A-B141-DEBBC6B07122

P577

Q28348036-731B82EC-8957-48F1-BF42-2725B774A828

P5875

Q28348036-1B3F9C3C-42DE-4022-8C5A-ED23C67EB428

P6179

Q28348036-173B3B4C-393F-4492-B153-911EBCECE069

P698

Q28348036-1F9DC96B-79CC-4990-9D32-26DE6752815E

P921

Q28348036-0F20AB10-5E77-497A-AB4C-494F6BFEDFEE

Q28348036-4AF3E1FC-1B9E-4DE1-8566-EEBDCE3932CA

P932

Q28348036-787D435B-BB55-40AA-A81A-75F159100B48

P3181

P356

P1433

British Journal of Cancer

P1476

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

@en

P2093

A F de Goeij

http://www.w3.org/2001/XMLSchema#string

A Font

http://www.w3.org/2001/XMLSchema#string

A J Senagore

http://www.w3.org/2001/XMLSchema#string

A R Norman

http://www.w3.org/2001/XMLSchema#string

A Rapallo

http://www.w3.org/2001/XMLSchema#string

A Russo

http://www.w3.org/2001/XMLSchema#string

B J Iacopetta

http://www.w3.org/2001/XMLSchema#string

B R Dix

http://www.w3.org/2001/XMLSchema#string

C Faber

http://www.w3.org/2001/XMLSchema#string

C N Hall

http://www.w3.org/2001/XMLSchema#string

P2888

P304

692-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

417354

http://www.w3.org/2001/XMLSchema#string

P356

10.1054/BJOC.2001.1964

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P50

Pierre Laurent-Puig

David Cunningham

Nicholas J. Hawkins

Gustav Gaudernack

P577

2001-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11815404

http://www.w3.org/2001/XMLSchema#string

P6179

1020621721

http://www.w3.org/2001/XMLSchema#string

P698

11531254

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

2364126

http://www.w3.org/2001/XMLSchema#string